BioNTech (BNTX) Financial Analysis & Valuation | Quarter Chart
BioNTech (BNTX)
BNTXPrice: $94.26
Fair Value: 🔒
🔒score
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial fo... more
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and oth... more
Description
Shares
| Market Cap | $23.84B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | DE | CEO | Ugur Sahin |
| IPO Date | 2019-10-10 | CAGR | 0.61% |
| Employees | 6,772 | Website | www.biontech.de |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
BNTX chart loading...
Fundamentals
Technicals
| Enterprise Value | $10.33B | P/E Ratio | -20.4 |
| Forward P/E | -21.3 | PEG Ratio | — |
| P/S Ratio | 7.47 | P/B Ratio | 1.12 |
| P/CF Ratio | 23.96 | P/FCF Ratio | 30.68 |
| EPS | $-4.62 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 1.91% | Gross Margin | 0.78% |
| Operating Margin | -0.52% | Profit Margin | -0.45% |
| ROE | -0.07% | ROA | -0.06% |
| ROCE | -0.08% | Current Ratio | 8.8 |
| Quick Ratio | 8.74 | Cash Ratio | 5.63 |
| Debt/Equity | 0.02 | Interest Coverage | -67.92 |
| Altman Z Score | 7.07 | Piotroski Score | 4 |